A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00857766 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: ADVAIR DISKUS™ 250/50mcg
OTHER: Placebo

Sponsor

GlaxoSmithKline